AI-Powered Compound Analysis & Indication Mapping
| Compound ID | Original Indication | New Target | Repurposing Score | Status |
|---|---|---|---|---|
| Metformin | Type 2 Diabetes | Longevity / AMPK | 0.88 | ACTIVE STUDY |
| Sirolimus | Immunosuppressant | Cellular Senescence | 0.94 | CANDIDATE |
| Dasatinib | Leukemia | Senolytic Clearance | 0.82 | CANDIDATE |
"I've identified 14 high-confidence candidates for repurposing towards SIRT1 activation. Compound APP-442 shows a 22% better binding affinity than previous benchmarks."